- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- Bordetella pertussis toxin (PT) antibody
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- Cytomegalovirus (CMV) IgG avidity
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diagnosis of Intestinal Parasites
- Drug Monitoring, Antidepressants, With Confirmation, Urine and Serum
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Factor VIII Activity, Clotting
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Viral RNA, Genotype, LiPA
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV Pre-exposure Prophylaxis (PrEP) Testing
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- LDL Cholesterol Calculations
- LeukoVantage® Myeloid Neoplasm Mutation Panels
- Lupus Anticoagulant (LA) Evaluation with Reflex
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Myeloproliferative Neoplasm Diagnosis: Molecular Evaluation
- No FAQs found
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- Pharmacogenomics Panel
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
T-SPOT®.TBTest code(s) 37737
Question 1. What is the T-SPOT®.TB (T-SPOT.TB) test?
The T-SPOT®.TB test is an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by Mycobacterium tuberculosis antigens ESAT-6 and CFP 10 by capturing interferon gamma (IFN- γ) in the vicinity of T cells in human whole blood collected in sodium citrate or sodium or lithium heparin. It is intended for use as an aid in the diagnosis of M tuberculosis infection.
The T-SPOT.TB test is an indirect test for M tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations.
Question 2. How does the T-SPOT.TB test work?
The T-SPOT.TB assay is a blood test for M tuberculosis infection that is based on measurement of a cell-mediated immune response. The peptide cocktail simulating the mycobacterial proteins ESAT-6 and CFP-10 stimulates the patient’s T-cells in vitro to release IFN- γ, which is then measured using the enzyme-linked immunospot (ELISPOT) methodology.
Peripheral blood mononuclear cells (PBMCs) are separated from a whole blood specimen, washed, and then counted before being added into the assay.
Isolated PBMCs are exposed to a phytohemagglutinin control, nil control, and 2 separate panels of M tuberculosis specific antigens. Enumerating the spots provides a measurement of the abundance of M tuberculosis-sensitive cells in the peripheral blood. Please refer to the package insert for full information on assay methodology.1
Question 3. What are the advantages of T-SPOT.TB, or interferon gamma releasing assay (IGRA), over TST?
IGRA testing has a number of advantages over a tuberculin skin test (TST), including:
- Results are not subject to reader bias.
- Accuracy is not affected by prior bacille Calmette-Guerin (BCG) vaccination.
- Requires only 1 patient visit (2-4 required for TST).
- Reduced staff time and avoidance of unnecessary follow-up, additional treatment, and treatment due to false-positive TST results.2
Question 4. How do you interpret the results of T-SPOT.TB?
T-SPOT.TB test results are reported as positive, negative, or borderline (equivocal). For all samples, the test controls, positive and negative, must perform as expected. Test results are determined by enumerating the spots (captured interferon-gamma from individual T cells) in each of the patient’s 4 test wells (Positive Control, Nil Control, Panel A, Panel B). Qualitative results for the T-SPOT.TB test are interpreted by subtracting the spot count in the Nil control well from the spot count in each of the Panels, according to the following algorithm:
Positive:The test result is Positive if (Panel A-Nil) and/or (Panel B-Nil) spot count is ≥ 8.
Negative:The test result is Negative if both (Panel A-Nil) and (Panel B-Nil) spot counts are ≤ 4, including values <0.
Borderline (equivocal):Results where the highest of the Panel A or Panel B spot count is 5, 6, or 7 spots are considered Borderline (equivocal); retesting by collecting another patient specimen is recommended.
If the result is still Borderline (equivocal) on retesting with another specimen, then other diagnostic tests and/or epidemiologic information should be used to help determine the tuberculosis (TB) infection status of the patient.
Please refer to the package insert for full information on result reporting/interpretation.1
Question 5. What are conversion and reversion?
Conversion: With respect to TB antigens, conversion is the point at which IFN-γ becomes detectable above the established threshold or cutoff from a previous negative or unknown result (negative to positive). In a study of over 16,000 healthcare workers across 19 US hospitals, the mean conversion rate was 0.8% (range, 0.0-2.5%).6
Conversion rates correlate with geographic incidence of TB and/or known TB risk factors. For patients and health care workers with weak-positive results in low-risk settings, Centers for Disease Control and Prevention (CDC) guidelines recommend retesting with an equivalent or other test while considering the full clinical picture and risk/exposure assessment.6
Reversion: The opposite of conversion—a result that goes from above the established cutoff to below the cutoff (positive to a negative). In a study of over 16,000 healthcare workers across 19 US hospitals, the mean reversion rate was 17.6%. Hospitals using T-SPOT.TB to evaluate only high-risk healthcare workers trended lower in reversion rate (mean 13.9%) when compared to hospitals evaluating all healthcare workers (mean 20.7%).6
Question 6. What causes an invalid result?
Results are considered invalid for any of the following reasons:
- Nil well develops >10 spots
- Mitogen well develops <20 spots (unless Panel A-Nil and/or Panel B-Nil are Positive or Borderline)
- High background staining hinders discrimination of the spots from the background in the microwells
Invalid results can be due to 1 or more of the following:
- Operator/testing issues
- Medium contamination
- Improper specimen handling
- Improper separation of PBMCs
- Patient health (ie, low PBMC count leading to inadequate response mitogen)
- Inadequate response to mitogen without known cause
Repeat testing by collecting another specimen is recommended for invalid results.
Question 7. Can T-SPOT.TB testing be used to monitor TB therapy?
No. The T-SPOT.TB test has not been evaluated in individuals who have received >1 month of anti-TB therapy.1
Question 8. Does prior TST affect a T-SPOT.TB result?
Yes, a prior TST can boost IGRA results. However, boosting does not occur in uninfected individuals, because they do not have an established immune response to TB. Furthermore, the TST, despite its in vivo application, does not cause sensitization or establish a cell-mediated response. Therefore, it cannot cause subsequent boosting among persons without prior TB infection. The implications of a boosted response are unknown. However, a boosted response is thought to reflect the induction of a weak memory response from multiple points of stimulation. Boosting is a common phenomenon when a TST is repeated. Each TST can boost subsequent TST responses, due to remote TB infection, as well as infection with non-tuberculous mycobacteria or vaccination with BCG.5,7,8
Question 9. Can IGRAs be given to persons receiving vaccinations?
The effect of live virus vaccination on IGRAs has not been studied. However, it is advisable that the IGRA sample be drawn on the same day as vaccination or 4 to 6 weeks after the administration of a live-virus vaccine.
Question 10. Can IGRAs be used in children?
Yes. An IGRA can be used for children 2 years of age or older. It is preferred in children who have had the BCG vaccine or are unlikely to return for a TST to be read.
For children < 2 years of age, the TST is the preferred test to detect TB infection.4
T-SPOT.TB specimen requirements for children are as follows1:
- <2 years: 2 mL lithium heparin
- 2-10 years: 4 mL lithium heparin
- ≥10 years: 6 mL lithium heparin
- Oxford Immunotec Ltd. T-SPOT.TB .TB Package Insert PI-TB-US-V5. Abingdon, UK;2013.
- Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:e1-e33.
- Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77-87.
- American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:829-53.
- Daley CL, Reves RR, Beard MA, et al. A summary of meeting proceedings on addressing variability around the cut point in serial interferon-gamma release assay testing. Infect Control Hosp Epidemiol. 2013;34:625-630.
- King TC, Upfal M, Gottlieb A, et al. T-SPOT.TB interferon-γ release assay performance in healthcare worker screening at nineteen US hospitals. Am J Resp Crit Care Med. 2015;192:367-373.
- van Zyl-Smit RN, Zwerling A, Dheda K, et al. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One. 2009;4(12):e8517. doi:10.1371/journal.pone.0008517
- FAQs for Health Professionals: QuantiFERON®-TB Gold Plus. Qiagen; 2017. https://www.quantiferon.com/us/wp-content/uploads/sites/13/2017/10/PROM-11178-001_1107769_BRO-QFT-TB-Gold-Plus-FAQ-HCPs-0717-US.pdf. Accessed November 19, 2019.